Answers are grounded in this paper and cite their sources.
A green and efficient technique for synthesizing α-aminophosphonates (Alpha Aps) 7a–j has been developed through the Kabachnik–Fields (K-F) reaction, catalyzed by nano-BF₃·SiO₂ under solvent-free ultrasonication in good yields (94–98%). Target compounds were developed and prescreened using in silico ADME analysis and molecular docking to establish their drug-like characteristics and potential as α-amylase inhibitors. In vitro α-amylase inhibition experiments were used to determine the biological activity of the produced compounds, which were further characterized structurally using spectroscopy. Compounds 7h (2H-1,3-anthracenyl, IC₅₀ = 86.9 ± 0.4 μg/mL), 7f (naphthalenyl, IC₅₀ = 89.5 ± 0.4 μg/mL), and 7e (1H-indol-5-yl, IC₅₀ = 91.4 ± 0.2 μg/mL) outperformed the reference medication acarbose (IC₅₀ = 92.8 ± 0.6 μg). Compounds 7c and 7i showed inhibition comparable to acarbose, while 7a, 7b, 7d, 7 g, and 7j demonstrated moderate activity (IC₅₀: 105.0–132.7 μg/mL). These findings emphasize the potential of α-aminophosphonate derivatives as next-generation α-amylase inhibitors. They also provide crucial structural insights for future diabetic medication design.
No takes yet. Share an insight, caveat, or question.
Basha et al. (2026) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: